FARMACIA HOSPITALARIA最新文献

{"title":"In vitro assay of pharmacobezoar formation with extended-release divalproex sodium tablets.","authors":"Thais Lizondo López, Silvia González Suárez, Carmen López-Cabezas, Judit Julian Peña, Naira Rico Santana, Dolors Soy Muner, Núria Fernández Hernández, Emilio Salgado García","doi":"10.1016/j.farma.2025.06.013","DOIUrl":"https://doi.org/10.1016/j.farma.2025.06.013","url":null,"abstract":"<p><strong>Objective: </strong>To assess pharmacobezoar formation in a case of intoxication following the massive ingestion of extended-release divalproex sodium tablets, using an in vitro model conducted in the pharmacy laboratory.</p><p><strong>Methods: </strong>An in vitro model was created to simulate gastric conditions and evaluate pharmacobezoar formation. Simulated gastric fluid was prepared according to the European Pharmacopeia procedure. The conglomerate's size and pH were measured at 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, and 24 h intervals. Serum valproic acid concentrations were determined at all mentioned time points and then compared with the patient's serum concentrations.</p><p><strong>Results: </strong>The in vitro model revealed the formation of a solid pharmacobezoar (5 cm x 6 cm) after 2 h (pH = 1.5), which remained stable for 24 h. The peak serum concentration of valproic acid occurred approximately 22 h post-ingestion, reaching 656 μg/mL. The in vitro assay indicated a similar peak concentration around 24 h after the tablets were immersed in the simulated gastric fluid.</p><p><strong>Conclusions: </strong>The experiment conducted supports the hypothesis of pharmacobezoar formation following excessive ingestion of extended-release divalproex sodium tablets. Understanding which drug formulations can potentially cause pharmacobezoars formation is crucial for toxicological management.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Qualitative study on the adoption and enhancement of the capacity-motivation-opportunity model for pharmaceutical care in outpatient pharmacy consultations in Spain.","authors":"Ana María Álvarez-Díaz, Carlos Crespo Diz, Emilio Monte Boquet, José Antonio Marcos Rodríguez, Luis Margusino Framinan, Elena Sánchez Yañez, Manuel Vélez-Díaz-Pallarés, Esther Vicente Escrig, Ramón Morillo-Verdugo","doi":"10.1016/j.farma.2025.05.002","DOIUrl":"https://doi.org/10.1016/j.farma.2025.05.002","url":null,"abstract":"<p><strong>Objective: </strong>To analyse and address the barriers that Pharmacy Services encounter when adopting the capacity-motivation-opportunity (CMO) pharmaceutical care model in outpatient consultations, identifying the relevant actors in the ecosystem, as well as the motivations. Finally, to make a first approach to solutions that will help us to select those that could be developed through future initiatives.</p><p><strong>Method: </strong>A structured methodology was developed in several phases. Two teams were formed: the \"Core Team,\" consisting of hospital pharmacists with experience in pharmaceutical care and patient-centered care, and the \"Guiding Team,\" made up of professionals from various disciplines. The first phase included an online prospecting workshop to explore the phases of model adoption. Subsequently, semi-structured interviews were conducted with key actors, such as physicians, managers, and patient associations, to identify needs and barriers. Finally, a face-to-face workshop was organized to facilitate the ideation and validation of solutions.</p><p><strong>Results: </strong>Three categories of actors in the CMO model ecosystem were identified: interested agents (beneficiaries), interesting agents (influencers), and executive agents (implementers). Significant barriers were found, including variability in infrastructure, lack of commitment from managers, and the workload of pharmacists. However, there was also growing motivation among professionals and organizations to adopt the model. During the ideation workshop, ten initiatives were prioritized, including the use of digital technologies and ongoing training programs.</p><p><strong>Conclusions: </strong>The study highlights the high potential of the CMO model to improve pharmaceutical care in outpatient settings in Spain, despite the identified barriers. The proposed strategies, focused on digitalization and multidisciplinary collaboration, are essential for effective implementation. Future research is suggested to evaluate the long-term impact of these initiatives and to strengthen the involvement of patient associations and other actors in the adoption process.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144718864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Network meta-analysis of perioperative immunotherapies in non-small-cell lung cancer according to tumor programmed death ligand 1 expression.","authors":"Manuel David Gil-Sierra, María Del Pilar Briceño-Casado, Cristina Moreno-Ramos","doi":"10.1016/j.farma.2025.05.011","DOIUrl":"https://doi.org/10.1016/j.farma.2025.05.011","url":null,"abstract":"<p><strong>Objective: </strong>Immunotherapy has emerged as a therapeutic alternative to chemotherapy (CT) for perioperative treatment of resectable non-small cell lung cancer (NSCLC). The objective is to perform a network meta-analysis comparing the perioperative efficacy of immunotherapies in resectable NSCLC taking into account tumor expression of programmed death ligand 1 (PD-L1).</p><p><strong>Method: </strong>A review was performed in Pubmed® and EMBASE® until September 17, 2024. Phase III clinical trials on perioperative immunotherapies (P-) for resectable NSCLC with ≥50 patients were included. The selected endpoint was progression-free survival (PFS) according to different levels of PD-L1 expression. The statistical analysis used Bayesian methods. Fixed- or random-effects models were assessed using deviance information criteria (DIC). A sensitivity analysis was developed to evaluate the influence of heterogeneous studies.</p><p><strong>Results: </strong>Four trials were included. Immunotherapeutic schemes with P-toripalimab, P-nivolumab, P-pembrolizumab and P-durvalumab were selected. Only P-toripalimab included a cycle of adjuvant toripalimab + CT. The remaining perioperative combinations contained the neoadjuvant immunotherapeutic agent + CT (4 cycles) regimen followed by adjuvant immunotherapy. The common comparator was neoadjuvant placebo + CT with adjuvant placebo (P-placebo). P-toripalimab was evaluated in a population with heterogeneous characteristics. Fixed effects model was selected for DIC values with irrelevant differences. P-toripalimab obtained greater magnitude of effect in PFS for populations with PD-L1 < 1% and 1-49% (reference treatment). No benefit of any immunotherapeutic combination over P-placebo was observed in resectable NSCLC with PD-L1 expression <1%. P-toripalimab was statistically superior to the other regimens [except P-pembrolizumab, HR = 1.6 (95%CrI: 0.84-3.2)] for PD-L1 expression 1-49%. Immunotherapeutic schemes were superior to p-placebo for PD-L1 expression ≥50%. Sensitivity analysis showed results compatible with the primary analysis.</p><p><strong>Conclusions: </strong>Our network meta-analysis provides reliable evidence on the efficacy of perioperative immunotherapy in resectable NSCLC according to PD-L1 expression levels, and may favor competition between therapeutic alternatives. A sensitivity analysis supported these results.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144718865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Caplacizumab in acute thrombotic thrombocytopenic purpura refractory to standard treatment.","authors":"Yeray Reyes-de-la-Mata, Gala Cano-Martínez, Francisco Javier Salmerón-Navas, Carmen María Domínguez-Santana, Silvia Fenix-Caballero","doi":"10.1016/j.farma.2025.05.016","DOIUrl":"https://doi.org/10.1016/j.farma.2025.05.016","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144718863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete resolution of rupiaceous psoriasis associated with arthropathy with guselkumab: A case report.","authors":"Andrea Pinilla Rello, Eva Queipo García, M Victoria Corriol Pallas, Adrian Diago Irache","doi":"10.1016/j.farma.2025.06.003","DOIUrl":"https://doi.org/10.1016/j.farma.2025.06.003","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New Alzheimer disease's treatments: Hope or disappointment.","authors":"Daniel Sevilla-Sánchez, Alejandro J Garza-Martínez","doi":"10.1016/j.farma.2025.06.004","DOIUrl":"https://doi.org/10.1016/j.farma.2025.06.004","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Development of the mobile application Guide to medication reconciliation in the critically ill patient.","authors":"María Martín Cerezuela, Fernando Becerril Moreno, Jesús Ruiz Ramos, Ana de Lorenzo Pinto, Esther Domingo Chiva, Marta Valera Rubio, Irene Aquerreta González, Carla Bastida Fernández, Laura Doménech Moral, Amaia Egüés Lugea, Miguel Ángel Amor García, Tatiana Betancor García, Sara Cobo Sacristán, Marta Albanell Fernández, Sara Ortiz Pérez, Luis Pérez de Amezaga Tomás","doi":"10.1016/j.farma.2025.06.007","DOIUrl":"https://doi.org/10.1016/j.farma.2025.06.007","url":null,"abstract":"<p><strong>Objective: </strong>Medication reconciliation is an essential process in the care of critically ill patients, ensuring that patients' chronic medication is adapted to the patient's clinical situation and administered safely during hospitalisation. Given the profile of the patient admitted to a critical care unit (ICU), this becomes even more relevant. Reconciliation minimises possible medication errors and adverse effects, improving safety in the critically ill patient.</p><p><strong>Methods: </strong>The project, carried out between 2021 and 2024, was led by the FarMIC (Pharmacists in Intensive Care Medicine and Critical Care) and RedFaster (Pharmaceutical Care in Emergencies) groups of the Spanish Society of Hospital Pharmacy (SEFH), and included: selection of the drugs, review of the available literature and previous conciliation guidelines in similar areas of application, preparation of the drug information with the recommendations issued by the working group, the review of the same and the development of the mobile application.</p><p><strong>Results: </strong>In October 2024, the app 'Conciliation Guide for Critically Ill Patients®' was published, available free of charge for iOS and Android. It provides a drug index with detailed information on medication reintroduction schedules, routes of administration, monitoring, and drug-specific considerations. In addition, the tool includes information on withdrawal syndromes, drug-drug interactions with the usual ICU drugs and hazardous drugs information according to the NIOSH list.</p><p><strong>Conclusions: </strong>This app facilitates pharmacotherapeutic reconciliation process in the ICU, supporting healthcare professionals in making personalised decisions. Its use can optimise patient safety, reduce adverse events and improve critical patient care. Finally, this tool reinforces the role of the clinical pharmacist in the ICU, who must lead this process in all care transitions and adapt it to the clinical situation of the patient.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sepsis and septic shock.","authors":"Carla Bastida, Amaia Egües Lugea, Aurora Fernández Polo, Fernando Becerril Moreno, Maria Martín Cerezuela, Esther Domingo Chiva, Tatiana Betancor García, Miguel Angel Amor García, Irene Aquerreta González, Marta Albanell-Fernández, Laura Doménech Moral, Sara Ortiz Pérez, Sara Cobo Sacristán","doi":"10.1016/j.farma.2025.05.009","DOIUrl":"https://doi.org/10.1016/j.farma.2025.05.009","url":null,"abstract":"<p><p>Sepsis and septic shock are major global health issues, with significant morbidity and mortality. Early identification and appropriate management during the first few hours are crucial for improving clinical outcomes. Sepsis treatment focuses on infection control, restoration of perfusion, and the implementation of adjunctive therapies. A thorough understanding of these approaches is essential for the clinical pharmacist in the intensive care unit to provide optimal pharmacotherapeutic validation.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144620795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extravasations of non-cytotoxic drugs: A survey on pharmacist involvement in Spanish hospitals.","authors":"Inés Jiménez-Lozano, Jose Manuel Caro-Teller, Montserrat Pérez-Encinas, Helena Esteban Cartelle, Juan Manuel Rodríguez-Camacho, María José Fernández-Megía, Sergio Plata Paniagua, María José Otero","doi":"10.1016/j.farma.2025.06.011","DOIUrl":"https://doi.org/10.1016/j.farma.2025.06.011","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to evaluate the involvement of hospital pharmacists in the protocolization, management and clinical follow-up of non-cytotoxic drug extravasations in Spanish hospitals.</p><p><strong>Methods: </strong>A survey was distributed through the SEFH email list using the REDCap® web platform. The characteristics of the participating hospitals, the availability of a protocol for managing non-cytotoxic drug extravasations, the healthcare professionals involved in developing the protocol, and the pharmacists' involvement and clinical follow-up in response to these incidents were investigated.</p><p><strong>Results: </strong>A total of 89 complete responses were obtained from hospitals across 14 Autonomous Communities. Only 12 centers (13.5%) had a protocol that included recommendations for the extravasation of non-cytotoxic drugs, and in 11 (91.7%) of these, the pharmacist had participated in its development. The recommendations for extravasation management were mainly based on intrinsic drug properties such as pH and osmolarity, specific properties like vasoconstrictor drugs, or the classification of drugs as vesicants, irritants, or non-irritants. Wide variability was observed in recommendations regarding the application of cold or heat and hyaluronidase dosage. The decision to consult with pharmacy service regarding the management of extravasation depended largely on the individual nurse or physician's judgment, but 20 centers (22.5%) reported that they never received such consultations. A large proportion of Pharmacy Services (73.0%) reported that they participate in extravasation management by providing information by telephone, but 21 centers (23.6%) indicated that the pharmacist never participates in these adverse events. Limited involvement was also noted in the clinical assessment of the patient, follow-up of the extravasation, and documentation in the patient's medical history.</p><p><strong>Conclusion: </strong>The results of this survey reflect the limited standardization in the management of non-cytotoxic drug extravasations, as well as significant heterogeneity in the level of involvement of hospital pharmacists in these adverse events across hospitals in our country. The need to establish a national guideline or document on the management of non-cytotoxic drug extravasations is highlighted, along with the importance of promoting interdisciplinary collaboration to improve patient safety.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144620794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design and validation of IF-CSS frailty index based on the comprehensive geriatric assessment for its application in nursing homes.","authors":"Juan Francisco Peris-Martí, Elia M Fernández-Villalba, Patricia Bravo-José, Carmen Isabel Sáez-Lleó, Minerva Espert-Roig, Pilar Martínez-Antequera","doi":"10.1016/j.farma.2025.06.002","DOIUrl":"https://doi.org/10.1016/j.farma.2025.06.002","url":null,"abstract":"<p><strong>Objective: </strong>To validate the IF-CSS frailty index according to its predictive capacity for mortality and to define the intervals compatible with frailty states.</p><p><strong>Methods: </strong>An observational, retrospective, multicenter study of a cohort of elderly patients from four nursing homes with a follow up between 12 and 38 months was conducted. The IF-CSS comprised 17 variables across four domains from the comprehensive geriatric assessment. Contrast of hypothesis log-rank for survival curves according to IF-CSS index was performed. The predictive model of survival time was performed using a parametric accelerated failure model.</p><p><strong>Results: </strong>535 patients with a mean age of 83.62 years (DE±7.84) were included. Mortality rate during the study period was 39.8%. Survival curves by frailty intervals showed significant differences (χ² = 92; p < 0.001). The comparative analysis also showed significant differences for almost all the variables included in the construct. The parametric model of accelerated failure estimated a 29% reduction in survival time for each tenth of an increase in the IF-CSS.</p><p><strong>Conclusions: </strong>The IF-CSS results in a tool with a frailty discriminative and mortality predictive capacity that allows its use in the care programs of nursing homes.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144620793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}